Tocagen Inc. (TOCA): Price and Financial Metrics
TOCA Price/Volume Stats
| Current price | $1.26 | 52-week high | $6.77 |
| Prev. close | $1.31 | 52-week low | $0.42 |
| Day low | $1.22 | Volume | 761,400 |
| Day high | $1.50 | Avg. volume | 1,472,422 |
| 50-day MA | $1.24 | Dividend yield | N/A |
| 200-day MA | $1.04 | Market Cap | 30.14M |
TOCA Stock Price Chart Interactive Chart >
Tocagen Inc. (TOCA) Company Bio
Tocagen Inc., a clinical-stage company, focuses on developing gene therapy candidates to activate a patient’s immune system against their cancer in the United States. The company is developing Toca 511 & Toca FC that is in Phase II/III clinical trial for patients with recurrent high grade glioma (HGG); and Phase Ib clinical trial for the intravenous treatment of metastatic colorectal, pancreatic, breast, lung, melanoma, and renal cancers, as well as in preclinical stage for newly diagnosed HGG. The company was founded in 2007 and is based in San Diego, California.
Latest TOCA News From Around the Web
Below are the latest news stories about Tocagen Inc that investors may wish to consider to help them evaluate TOCA as an investment opportunity.
Tocagen Announces Change to Virtual Format for Special Meeting of StockholdersTocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, it is changing its special meeting of stockholders related to its previously announced proposed merger with Forte Biosciences, Inc. (the "Special Meeting") to a virtual-only format that will be held via live audio webcast. |
Tocagen Reports First Quarter 2020 Financial ResultsSAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2020. On February 19, 2020, Tocagen announced it had entered into a… |
Tocagen Reports Fourth Quarter and Full Year 2019 Financial ResultsSAN DIEGO, Feb. 27, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. "Following our extensive review of… |
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome StudyHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ... |
Tocagen and Forte Biosciences Announce MergerSAN DIEGO and TORRANCE, Calif., Feb. 19, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they… |
TOCA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | -87.88% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | -93.51% |
Continue Researching TOCA
Here are a few links from around the web to help you further your research on Tocagen Inc's stock as an investment opportunity:Tocagen Inc (TOCA) Stock Price | Nasdaq
Tocagen Inc (TOCA) Stock Quote, History and News - Yahoo Finance
Tocagen Inc (TOCA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...